Client News

Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program with evenamide as Add-on Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

NewronNotes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

DEBRA Research Collaborates with Queen Mary University of London to Advance Drug Development for Epidermolysis bullosa

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

PL BioScience Announces Major Site Expansion

CorTec Announces Neurotech Milestone: First Human Implantation of a Brain-Computer Interface made in Germany

Meliodays and Celanese Partner for Meliodays’ Development of Hormone-Free Non-Contraceptive IUD designed to Treat Menstrual Pain